Entero Therapeutics, Inc. (GRDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entero Therapeutics, Inc. (GRDX) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-855.69K) by net assets ($89.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Entero Therapeutics, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Entero Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Entero Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entero Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entero Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carver Bancorp Inc
NASDAQ:CARV
|
-0.059x |
|
Careteq Ltd
AU:CTQ
|
-0.265x |
|
TruCap Finance Limited
NSE:TRU
|
1.175x |
|
Kaili Resources Ltd
AU:KLR
|
0.016x |
|
Turbo Energy, S.A. American Depositary Shares
NASDAQ:TURB
|
-0.966x |
|
Worksport Ltd
NASDAQ:WKSP
|
-0.412x |
|
Iconic Minerals Ltd
V:ICM
|
-0.323x |
|
DGA Spólka Akcyjna
WAR:DGA
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Entero Therapeutics, Inc. from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Entero Therapeutics, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.80 Million | $-9.22 Million | -0.159x | +95.36% |
| 2023-12-31 | $3.60 Million | $-12.38 Million | -3.435x | +57.84% |
| 2022-12-31 | $2.74 Million | $-22.34 Million | -8.148x | -297.39% |
| 2021-12-31 | $-7.82 Million | $-32.29 Million | 4.128x | -2.86% |
| 2020-12-31 | $-2.64 Million | $-11.22 Million | 4.249x | +239.81% |
| 2019-12-31 | $4.62 Million | $-14.03 Million | -3.039x | -25.10% |
| 2018-12-31 | $4.47 Million | $-10.87 Million | -2.430x | +7.63% |
| 2017-12-31 | $2.73 Million | $-7.18 Million | -2.630x | -86.35% |
| 2016-12-31 | $3.21 Million | $-4.53 Million | -1.411x | -222.85% |
| 2015-12-31 | $-3.63 Million | $-4.17 Million | 1.149x | +402.06% |
| 2014-12-31 | $2.64 Million | $-1.01 Million | -0.380x | -631001.74% |
| 2013-12-31 | $-938.31K | $56.55 | 0.000x | -- |
About Entero Therapeutics, Inc.
GridAI Technologies Corp. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more